American Association for Cancer Research

Continuing Medical Education (CME)

AACR-IASLC Joint Lung Cancer Conference 2014


The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.


The AACR has designated this live activity for a maximum of 21.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.


Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the CME Request for Credit Survey by Thursday, February 20, 2014. Certificates will only be issued to those who complete the survey.  Your CME certificate will be sent to you via email after the completion of the activity.


Lung cancer is not only the leading cause of cancer death in the United States, but also globally. The American Cancer Society estimates there will be just over 228,000 new cases of lung cancer in 2013 resulting in an estimated 159,400 deaths, which is over 25% of all cancer-related deaths in the United States2. Although this number is declining due to prevention efforts, the number represents a staggering health issue in our country. In the United States, about 40% of new cases of lung cancer arise in current smokers, 40% in former smokers, and 20% in never-smokers1. The mortality rate due to lung cancer in the United States is greater than that of the two most commonly diagnosed cancers in males (prostate) and females (breast). Lung cancer complexity is compounded by the fact that a combination of environmental and genetic factors contribute to the development of the disease.

Within the last 15 years, research has provided insights into the molecular nuances that stratify different types of non-small-cell lung cancer (NSCLC). In the past, an approach to target all NSCLC with cytotoxic chemotherapeutic agents, a “one size fits all approach,” provided a small measureable benefit but often with response rates of less than 20%3. Current research aims for personalized treatment options by characterizing the primary and specific genetic alterations in an individual patient’s tumor. Identifying therapeutic targets, verifying these targets, developing and testing therapeutics for optimal treatment, and evaluating mechanisms of resistance should treatment fail are processes requiring a multi-disciplinary approach and collaborative efforts.

Bridging the gap between what physicians understand about cancer biology and its application to clinical oncology is critical to the implementation of the most current, approved molecular-based tests to aid in the diagnosis, treatment and prevention of cancer.  Moreover, facilitating the interface between physicians and scientists will increase physicians’ knowledge of the epidemiological implications of lung cancer incidence and the contributions of laboratory research to drug development and alternate strategies should a cancer become resistant to therapy.

After participating in this CME activity, physicians should be able to:

  • To provide an overview of the current state of basic and early phase translational lung cancer in the areas of small cell lung cancer, pathology, molecular targets (such as RAS), immunotherapy, animal models, screening/prevention, and drug resistance, through a series of lectures given by nationally and internationally renowned scientists from diverse backgrounds. 
  • To illustrate important aspects of clinical trial design and master protocols through lectures and a series of examples of current clinical trials in lung cancer.
  • To educate more junior investigators and students in this field of research on advances and technologies, and to encourage them to initiate investigations in lung cancer research.
  • To accelerate translational and clinical research in the field and stimulate transdisciplinary information exchange by bringing together a broad range of scientists, including clinicians, basic, translational, and clinical researchers from academia and industry, as well as patient advocates.
  • To offer a forum for open discussion, scientific interaction, and collaboration among scientists with complementary expertise through the cooperation of the two associations, the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC). 


It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR will provide information that Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.


This activity is supported by grants and will be disclosed at the activity. 


Please contact the Office of CME at 215-440-9300 or